Company overview
Cyprotex provides specialized ADME-Tox services, including in vitro screening, mechanistic toxicology, high content 3D tissue analysis, and pharmacokinetic predictions via Cloe PK. They support drug discovery from early stages to regulatory submission with high-throughput assays, immunotoxicology, gene therapy capabilities, and AI-driven data generation. As part of Evotec, Cyprotex delivers rapid turnaround times of 5-10 working days for standard screens using validated in vitro and in silico methods.
Cyprotex ADME-Tox Solutions is listed in the NovaPharmaNews Supplier Hub as a CRO & Clinical Services partner serving United States & Americas. Core focus areas include adme screening, mechanistic toxicology, cyprotex, in vitro assays, pharmacokinetic prediction.
Industry categories: CRO & Clinical Services. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Products and technologies associated with Cyprotex ADME-Tox Solutions include Assay — relevant for pharmaceutical discovery, process development, and GMP manufacturing workflows.
Structured facts
- Website
- https://www.evotec.com/solutions/drug-discovery-preclinical-development/cyprotex-adme-tox-solutions
- Categories
- CRO & Clinical Services
- Markets served
- United States & Americas
- Keywords
- adme screening, mechanistic toxicology, cyprotex, in vitro assays, pharmacokinetic prediction
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What ADME-Tox capabilities does Cyprotex offer?
- Cyprotex offers in vitro ADME screening, mechanistic toxicology, high content 3D tissue analysis, mitochondrial toxicity, immunotoxicology, and Cloe PK for pharmacokinetic predictions across drug discovery and development.
- What is the typical turnaround time for Cyprotex services?
- Data for most standard screens is returned within 5-10 working days, supporting rapid decision-making in drug discovery.
- Does Cyprotex support regulatory studies and advanced modalities?
- Yes, Cyprotex provides regulatory in vitro ADME, DDI studies, gene therapy capabilities, biologics, oligonucleotides, and AI-optimized datasets from early discovery to preclinical and clinical stages.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
